DE60213648D1 - Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln - Google Patents

Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Info

Publication number
DE60213648D1
DE60213648D1 DE60213648T DE60213648T DE60213648D1 DE 60213648 D1 DE60213648 D1 DE 60213648D1 DE 60213648 T DE60213648 T DE 60213648T DE 60213648 T DE60213648 T DE 60213648T DE 60213648 D1 DE60213648 D1 DE 60213648D1
Authority
DE
Germany
Prior art keywords
pain
thymulental
peptides
preparation
thymulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213648T
Other languages
English (en)
Other versions
DE60213648T2 (de
Inventor
Mireille Dardenne
Jean-Marie Pleau
Jean-Francois Bach
Nayef Saade
Bared Safieh-Garabedian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saade Nayef Beirut Lb
Safieh-Garabedian Bared Beirut Lb
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE60213648D1 publication Critical patent/DE60213648D1/de
Publication of DE60213648T2 publication Critical patent/DE60213648T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60213648T 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln Expired - Lifetime DE60213648T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0112984A FR2830451B1 (fr) 2001-10-09 2001-10-09 Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
FR0112984 2001-10-09
PCT/FR2002/003428 WO2003030927A2 (fr) 2001-10-09 2002-10-08 Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur

Publications (2)

Publication Number Publication Date
DE60213648D1 true DE60213648D1 (de) 2006-09-14
DE60213648T2 DE60213648T2 (de) 2007-08-02

Family

ID=8868083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213648T Expired - Lifetime DE60213648T2 (de) 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Country Status (11)

Country Link
US (1) US7309690B2 (de)
EP (1) EP1450843B1 (de)
JP (1) JP4277684B2 (de)
AT (1) ATE334694T1 (de)
AU (1) AU2002362710B2 (de)
CA (1) CA2463549C (de)
DE (1) DE60213648T2 (de)
ES (1) ES2272811T3 (de)
FR (1) FR2830451B1 (de)
IL (2) IL161319A0 (de)
WO (1) WO2003030927A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途
EP2170930B3 (de) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2930156B1 (fr) * 2008-04-21 2011-10-28 Cll Pharma Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2657938T3 (es) 2008-12-31 2018-03-07 Ardelyx, Inc. Compuestos y métodos para inhibir el antipuerto mediado por NHE en el tratamiento de trastornos asociados a la retención de líquidos o a la sobrecarga de sales y trastornos del tracto gastrointestinal
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015003527A2 (pt) 2012-08-21 2017-07-04 Ardelyx Inc compostos e métodos para inibição de antiporte mediado por nhe no tratamento de desordens associadas à retenção de fluido ou sobrecarga de sal e desordens do trato gastrointestinal
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2983667B1 (de) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-bindende verbindungen und verfahren zur phosphattransporthemmung
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
CN109219444A (zh) * 2016-06-06 2019-01-15 临床干细胞有限公司 用于毛发生长的肽
MA47203A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Inhibiteurs d'antiport à médiation par nhe
MX2019008170A (es) 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301065A (en) * 1977-05-25 1981-11-17 Agence Nationale De Valorisation De La Recherche (Anvar) Novel polypeptides having thymic activity or an antagonistic activity and processes for their synthesis
GR75636B (de) * 1980-05-22 1984-08-02 Inst Nat Sante Rech Med
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
JPH06192120A (ja) * 1992-12-24 1994-07-12 Mitsui Toatsu Chem Inc 腎臓の組織・細胞の損傷・破壊の予防・治療剤
JP3751986B2 (ja) * 1994-06-21 2006-03-08 英良 横沢 医薬組成物
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US5808009A (en) * 1996-09-23 1998-09-15 North Dakota State University Research Foundation Method of affinity purifying antibodies

Also Published As

Publication number Publication date
FR2830451A1 (fr) 2003-04-11
US20050261194A1 (en) 2005-11-24
CA2463549C (fr) 2011-12-20
US7309690B2 (en) 2007-12-18
JP2005515972A (ja) 2005-06-02
EP1450843B1 (de) 2006-08-02
IL161319A0 (en) 2004-09-27
DE60213648T2 (de) 2007-08-02
JP4277684B2 (ja) 2009-06-10
ES2272811T3 (es) 2007-05-01
AU2002362710B2 (en) 2007-06-28
CA2463549A1 (fr) 2003-04-17
WO2003030927A2 (fr) 2003-04-17
IL161319A (en) 2008-11-26
EP1450843A2 (de) 2004-09-01
ATE334694T1 (de) 2006-08-15
WO2003030927A3 (fr) 2003-10-09
AU2002362710B8 (en) 2003-04-22
FR2830451B1 (fr) 2004-04-30

Similar Documents

Publication Publication Date Title
DE60213648D1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DE69934380D1 (de) Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
ATE362485T1 (de) Alloferone - immunomodulierende peptide
EP1319023B8 (de) Peptid aus hsp70 welches nk zellaktivität stimuliert und seine verwendung
GB2367061A (en) Peptides
DE69831257D1 (de) Histogranin peptide und deren analgetische verwendung
FI20050753A0 (fi) Uudet peptidit
IL149416A0 (en) Human enzymes of the metalloprotease family
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69738600D1 (de) Neuroaktive peptide
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
EP1303291A4 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
SE9703287D0 (sv) Peptides
ATE237345T1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
DE60329838D1 (de) Verwendung von alpha-s2 casein vorläufer-abgeleiteten peptiden
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks
TW200635950A (en) Specific binding agents of human angiopoietin-2
WO2000020572A3 (de) Gewebebindende peptide, ihre identifizierung, herstellung und verwendung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SAFIEH-GARABEDIAN, BARED, BEIRUT, LB

Owner name: SAADE, NAYEF, BEIRUT, LB

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, , FR

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

8364 No opposition during term of opposition
8381 Inventor (new situation)

Inventor name: DARDENNE, MIREILLE, F-75015 PARIS, FR

Inventor name: PLEAU, JEAN-MARIE, F-91120 PALAISEAU, FR

Inventor name: BACH, JEAN-FRANCOIS, F-75007 PARIS, FR

Inventor name: SAADE, NAYEF, BEYROUTH, LB

Inventor name: SAFIEH-GARABEDIAN, BARED, 1ST FLOOR, P.O. BOX , LB